CN Patent

CN105640918A — 4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮的制剂

Assigned to Celgene Corp · Expires 2016-06-08 · 10y expired

What this patent protects

本发明提供了4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮或其可药用立体异构体、前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。本发明还提供治疗、控制或预防诸如癌症或炎症性疾病等各种疾病的方法。

USPTO Abstract

本发明提供了4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮或其可药用立体异构体、前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。本发明还提供治疗、控制或预防诸如癌症或炎症性疾病等各种疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN105640918A
Jurisdiction
CN
Classification
—
Expires
2016-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.